Back to Search
Start Over
Guillain-Barré syndrome temporally associated with COVID-19 vaccines in Victoria, Australia.
- Source :
-
Vaccine [Vaccine] 2022 Dec 12; Vol. 40 (52), pp. 7579-7585. Date of Electronic Publication: 2022 Nov 07. - Publication Year :
- 2022
-
Abstract
- Guillain-Barré syndrome (GBS) is an adverse event of special interest (AESI) for surveillance systems monitoring adverse events following immunisation (AEFI) with COVID-19 vaccines. Emerging data support a temporal association between GBS and adenovirus-vector COVID-19 vaccines. We present a case series of GBS reports submitted between February and November 2021 to our enhanced spontaneous surveillance system (SAEFVIC) in Victoria, Australia, following vaccination with either the adenovirus-vector vaccine Vaxzevria ChadOx1-S (AstraZeneca) or an mRNA vaccine (Comirnaty BNT162b2 [Pfizer-BioNTech] or Spikevax mRNA-1273 [Moderna]). For each report, Brighton Collaboration case definitions were used to describe diagnostic certainty. Severity was graded using the GBS Disability Score. The observed incidence of GBS following immunisation against COVID-19 was compared to expected background ICD10-AM G61.0 coded hospitalisations. There were 41 total cases of GBS reported to SAEFVIC following Vaxzevria (n = 38), Comirnaty (n = 3), or Spikevax (n = 0) vaccines. The observed GBS incidence rate exceeded the expected background rate for Vaxzevria only, with 1.85 reports per 100,000 doses following dose 1, higher than the expected rate of 0.39 hospital admissions per 100,000 adults within 42 days of vaccination. Of 38 GBS reports following Vaxzevria, the median age at vaccination was 66 years and median onset of symptoms was 14 days following immunisation. There was one death. Four cases initially categorised as GBS were later reclassified as acute-onset chronic inflammatory demyelinating polyneuropathy. Fatigue was the predominant persisting symptom reported at follow up. Additional global studies are required to characterise risk factors, clinical variability, and to provide precision and generalizability regarding AEFI risks such as GBS associated with different vaccine platforms, which will help inform communication of the potential benefits and risks of COVID19 vaccination.<br />Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2022 Elsevier Ltd. All rights reserved.)
- Subjects :
- Adult
Humans
BNT162 Vaccine
Vaccination adverse effects
Victoria epidemiology
mRNA Vaccines adverse effects
ChAdOx1 nCoV-19
Male
Female
Middle Aged
Aged
Aged, 80 and over
COVID-19 epidemiology
COVID-19 prevention & control
COVID-19 Vaccines adverse effects
Guillain-Barre Syndrome chemically induced
Guillain-Barre Syndrome epidemiology
Subjects
Details
- Language :
- English
- ISSN :
- 1873-2518
- Volume :
- 40
- Issue :
- 52
- Database :
- MEDLINE
- Journal :
- Vaccine
- Publication Type :
- Academic Journal
- Accession number :
- 36357291
- Full Text :
- https://doi.org/10.1016/j.vaccine.2022.10.084